Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | 10.05 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 116.21 | 12.83 | 8.45 | 7.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +2317.8% | +180.4% | +123.2% | +84.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | 80.8% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | -1400.6% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | -1626.2% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -148.5% | -63.0% | -31.7% | -28.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -666.5% | -233.7% | -70.4% | +27.3% | |
| ROA | -809.3% | -403.5% | -739.2% | -330.8% | -232.4% | -106.7% | -94.6% | -106.0% | -154.2% | -70.3% | -56.3% | -90.0% | -112.8% | -21.5% | -78.3% | -62.0% | -46.2% | -42.6% | -31.5% | -19.5% | -19.4% |
| — | -278.0% | -681.4% | -212.0% | -50.7% | -51.9% | -68.1% | -17.8% | -36.7% | -227.5% | +28.1% | -45.2% | -144.0% | +49.6% | -148.7% | -218.4% | -138.3% | -206.3% | -127.9% | -45.9% | +31.1% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -382.4% | -197.0% | -134.2% | -78.5% | -90.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -322.6% | -158.3% | -81.1% | +12.4% | +60.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.15 | 0.60 | 0.38 | 0.26 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +1329.2% | +201.7% | +114.5% | +29.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.06 | 0.18 | 0.21 | 0.04 | 0.05 | 0.50 | 0.18 | 0.24 | 0.24 | 0.16 | 0.28 | 0.35 | 0.84 | 1.63 | 2.61 | 3.69 |
| — | -38.9% | -85.6% | -92.7% | -35.0% | +9.5% | -64.2% | +16.1% | -82.4% | -78.9% | +214.6% | -34.4% | -31.0% | -71.0% | -90.3% | -89.2% | -90.4% | -82.5% | -62.6% | -47.8% | -4.3% | |
| Quick Ratio | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.06 | 0.18 | 0.21 | 0.04 | 0.05 | 0.50 | 0.18 | 0.24 | 0.24 | 0.16 | 0.28 | 0.35 | 0.84 | 1.63 | 2.61 | 3.69 |
| — | -38.9% | -85.6% | -92.7% | -35.0% | +9.5% | -64.2% | +16.1% | -82.4% | -78.9% | +214.6% | -34.4% | -31.0% | -71.0% | -90.3% | -89.2% | -90.4% | -82.5% | -62.6% | -47.9% | -4.3% | |
| Interest Coverage | — | — | -14.93 | -25.26 | -6.80 | — | -7.80 | — | -48.32 | -56.44 | — | — | -60.63 | -49.88 | — | — | -47.72 | -402.41 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCLI stock.
Brainstorm Cell Therapeutics Inc.'s current P/E is -0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Brainstorm Cell Therapeutics Inc.'s business trajectory between earnings reports.